Retatrutide is a novel investigational peptide that acts as a triple agonist of GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. Early clinical trial data published in The New England Journal of Medicine (2023) demonstrated that participants with obesity who received retatrutide experienced substantial reductions in body weight—with some individuals losing over 24% of their body weight within 48 weeks. This magnitude of weight reduction is greater than what has been seen in trials of single or dual agonists, suggesting that retatrutide’s combined receptor activity could have significant metabolic benefits.
145 $
Fast Shipping
Most orders are processed out the same day they are placed.
It is essential to note that retatrutide is currently under investigation and is for research purposes only. While early data are promising, it has not been approved for clinical use, and its long-term safety and efficacy remain under study.
Application
• Supports Weight Management • May Improve Insulin Sensitivity • Helps Regulate Blood Glucose • Supports Cardiometabolic Health • Potential Benefits for Type 2 Diabetes and Fatty Liver Disease
